Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
IKNA Ikena Oncology Inc
- Stocks
- Healthcare
- NASDAQ: IKNA
Price (delayed)
$1.34
Market cap
$64.67M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.86
Enterprise value
$34.51M
Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing five programs that
Highlights
IKNA's EPS is up by 45% year-on-year and by 16% since the previous quarter
The company's net income rose by 40% YoY and by 15% QoQ
IKNA's quick ratio is down by 16% year-on-year but it is up by 12% since the previous quarter
Ikena Oncology's revenue has shrunk by 100% YoY
IKNA's gross profit has shrunk by 100% YoY
Key stats
What are the main financial stats of IKNA
Market
Valuations
Earnings
Shares outstanding
48.26M
Market cap
$64.67M
Enterprise value
$34.51M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.55
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$51.54M
Net income
-$41.71M
EBIT
-$41.55M
EBITDA
-$39.06M
Free cash flow
-$37.89M
Per share
Balance sheet
Liquidity
EPS
-$0.86
EPS diluted
-$0.86
Free cash flow per share
-$0.79
Book value per share
$2.45
Revenue per share
$0
TBVPS
$2.71
Total assets
$130.84M
Total liabilities
$12.59M
Debt
$6.61M
Equity
$118.25M
Working capital
$108.21M
Debt to equity
0.06
Current ratio
13.31
Quick ratio
12.97
Net debt/EBITDA
0.77
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-28.8%
Return on equity
-32%
Return on invested capital
-40.8%
Return on capital employed
-34%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IKNA stock price
How has the Ikena Oncology stock price performed over time
Intraday
-0.74%
1 week
16.52%
1 month
7.2%
1 year
-22.99%
YTD
-18.29%
QTD
4.69%
Financial performance
How have Ikena Oncology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$51.54M
Net income
-$41.71M
Gross margin
N/A
Net margin
N/A
Ikena Oncology's revenue has shrunk by 100% YoY
IKNA's gross profit has shrunk by 100% YoY
The company's net income rose by 40% YoY and by 15% QoQ
The operating income rose by 34% YoY and by 13% QoQ
Price vs fundamentals
How does IKNA's price correlate with its fundamentals
Growth
What is Ikena Oncology's growth rate over time
Valuation
What is Ikena Oncology stock price valuation
P/E
N/A
P/B
0.55
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
IKNA's EPS is up by 45% year-on-year and by 16% since the previous quarter
The stock's price to book (P/B) is 58% less than its 5-year quarterly average of 1.3 and 8% less than its last 4 quarters average of 0.6
IKNA's equity is down by 24% year-on-year and by 6% since the previous quarter
Ikena Oncology's revenue has shrunk by 100% YoY
Efficiency
How efficient is Ikena Oncology business performance
Ikena Oncology's ROIC has increased by 47% YoY and by 10% from the previous quarter
Ikena Oncology's ROE has increased by 27% YoY and by 9% from the previous quarter
IKNA's return on assets is up by 23% year-on-year and by 9% since the previous quarter
Dividends
What is IKNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IKNA.
Financial health
How did Ikena Oncology financials performed over time
Ikena Oncology's total liabilities has decreased by 28% YoY and by 19% from the previous quarter
The total assets has contracted by 24% YoY and by 8% from the previous quarter
The debt is 94% less than the equity
The debt has contracted by 32% YoY and by 12% from the previous quarter
IKNA's equity is down by 24% year-on-year and by 6% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.